title: Salivary duct carcinoma responding to trastuzumab-based therapy: case report and review of the literature.
abstract: BACKGROUND
  Salivary duct carcinoma (SDC) is a rare malignancy with a poor prognosis. Human epidermal growth factor receptor-2 (Her-2/neu) is overexpressed in SDC and, hence, HER-2/neu targeted therapy could be an option.
  
  
  METHODS
  A 72-year-old man presented with parotid swelling and cervical lymphadenopathy. He underwent a parotidectomy, modified radical neck dissection, and postoperative chemoradiation with cisplatin. A year later, he developed metastatic disease in the contralateral neck that was treated surgically with right axillary lymphadenopathy. He received radiation to both sites, concurrent with carboplatin. Two years later, he underwent resection of a lung metastasis. He then had progression in the axillary and mediastinal lymph nodes and received 5 cycles of docetaxel and trastuzumab followed by maintenance trastuzumab.
  
  
  RESULTS
  The patient had a partial response and restaging studies 9 months after therapy discontinuation did not show progression.
  
  
  CONCLUSIONS
  Trastuzumab-based therapy is a potential therapeutic option for patients with SDC.
authors.affiliation: Division of Oncology-Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska.
authors.forename: Jairam
authors.initials: J
authors.lastname: Krishnamurthy
authors.forename: Devi Mukkai
authors.initials: DM
authors.lastname: Krishnamurty
authors.forename: John J
authors.initials: JJ
authors.lastname: Baker
authors.forename: Weining
authors.initials: W
authors.lastname: Zhen
authors.forename: Daniel
authors.initials: D
authors.lastname: Lydiatt
authors.forename: Apar Kishor
authors.initials: AK
authors.lastname: Ganti
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D037981:Neck Dissection; D010307:Parotid Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D018987:Salivary Ducts / Q000473:pathology* / Q000601:surgery; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human
keywords: HER-2/neu; chemotherapy; salivary duct carcinoma; survival; trastuzumab